Omada Health (OMDA) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Omada Health (OMDA) has outperformed GeneDx (WGS) over the past year, losing 36.2% versus a loss of 69.0%. GeneDx is the larger company by market cap ($1.36 billion vs $736.4 million), about 1.9 times the size, while Omada Health is growing revenue faster (+53.2% vs +40.0%). On valuation, Omada Health trades at a lower forward P/E (17.2x vs 34.9x for GeneDx).
Omada Health converts more of its revenue into profit, with a net margin of -4.9% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMDA | WGS |
|---|---|---|
| Share price | $11.87 | $45.46 |
| Market cap | $736.39M | $1.36B |
| 1-day change | -5.04% | -7.68% |
| YTD return | -24.78% | -65.05% |
| 1-year return | -36.18% | -68.98% |
| 5-year return | — | -80.01% |
| P/E ratio (TTM) | 29.68 | — |
| Forward P/E | 17.18 | 34.93 |
| EPS (TTM) | $0.40 | $-3.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $260.21M | $427.54M |
| Revenue growth (YoY) | +53.24% | +39.97% |
| Net income (latest FY) | $-12.78M | $-21.02M |
| Gross margin | 65.69% | 69.74% |
| Operating margin | -4.60% | -3.06% |
| Net margin | -4.91% | -4.92% |
| 52-week high | $25.45 | $170.87 |
| 52-week low | $10.28 | $32.21 |
| Distance from 52-week high | -53.36% | -73.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +123.25% | +80.38% |
| Average volume | 1.33M | 869.34K |
| Shares outstanding | 62.04M | 29.97M |
| Employees | 980 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMDA has outperformed WGS by 32.8 percentage points over the past year.
- Omada Health grew revenue faster in its latest fiscal year (+53.24% vs +39.97%).
About Omada Health
OMDA stock →Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs.
Health Care · Medical/Nursing Services · 980 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
OMDA vs WGS FAQ
Which is bigger, Omada Health or GeneDx?
GeneDx (WGS) is larger, with a market capitalization of $1.36B compared with $736.39M for Omada Health (OMDA).
Which stock has performed better over the past year, OMDA or WGS?
OMDA returned -36.18% over the past 12 months, compared with -68.98% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are Omada Health and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.